Christine Sekaggya-Wiltshire

List of Publications by Year
in descending order

36	362	933447	940533
papers	citations	10 h-index	16 g-index

42	42	42	609
all docs	docs citations	times ranked	citing authors

#	ARTICLE	IF	CITATIONS
1	Stable warfarin dose prediction in subâ€Saharan African patients: A machineâ€learning approach and external validation of a clinical doseâ€“initiation algorithm. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 20-29.	2.5	10
2	Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda. Mycoses, 2022, 65, 625-634.	4.0	10
3	Developing and Validating a Clinical Warfarin Doseâ€Initiation Model for Blackâ€African Patients in South Africa and Uganda. Clinical Pharmacology and Therapeutics, 2021, 109, 1564-1574.	4.7	8
4	MicroRNAâ€122 and cytokeratinâ€18 have potential as a biomarkers of drugâ€induced liver injury in European and African patients on treatment for mycobacterial infection. British Journal of Clinical Pharmacology, 2021, 87, 3206-3217.	2.4	14
5	â€˜Out of sight, out of mind?â€™ A follow-up on HIV-infected patients with drug-resistant pulmonary tuberculosis in Uganda: A case series. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110197.	0.3	0
6	Anticoagulation in subâ€Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. British Journal of Clinical Pharmacology, 2021, 87, 3699-3705.	2.4	12
7	Internal Medicine Clerkship Amidst COVID-19 Pandemic: A Cross-Sectional Study of the Clinical Learning Experience of Undergraduate Medical Students at Makerere University, Uganda. Advances in Medical Education and Practice, 2021, Volume 12, 253-262.	1.5	11
8	Improving anticoagulation in subâ€Saharan Africa: What are the challenges and how can we overcome them?. British Journal of Clinical Pharmacology, 2021, 87, 3056-3068.	2.4	13
9	Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study. BMC Infectious Diseases, 2021, 21, 513.	2.9	4
10	Genetic factors associated with tuberculosis-related clinical outcomes in HIV-infected Black African patients: a systematic review and meta-analysis. Pharmacogenomics, 2021, 22, 997-1017.	1.3	0
11	Optimal therapy for multidrug-resistant tuberculosis and HIV. Lancet, The, 2020, 396, 363-365.	13.7	0
12	Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials, 2020, 21, 181.	1.6	14
13	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS ONE, 2020, 15, e0227458.	2.5	25
14	Utility of the monocyte to lymphocyte ratio in diagnosing latent tuberculosis among HIV-infected individuals with a negative tuberculosis symptom screen. PLoS ONE, 2020, 15, e0241786.	2.5	6
15	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
16	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
17	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
18	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0

#	Article	IF	Citations
19	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
20	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
21	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. Journal of Antimicrobial Chemotherapy, 2019, 74, 135-138.	3.0	7
22	Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 615-618.	3.3	6
23	Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
24	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. Open Forum Infectious Diseases, 2019, 6, ofz035.	0.9	5
25	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clinical Pharmacology and Therapeutics, 2019, 106, 450-457.	4.7	13
26	Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 481-487.	2.1	2
27	Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study. AIDS Research and Therapy, 2019, 16, 39.	1.7	5
28	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Journal of Antimicrobial Chemotherapy, 2019, 74, 468-472.	3.0	9
29	Delayed Sputum Culture Conversion in Tuberculosisâ€“Human Immunodeficiency Virusâ€“Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clinical Infectious Diseases, 2018, 67, 708-716.	5.8	34
30	The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. Tuberculosis, 2018, 108, 77-82.	1.9	14
31	Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort. PLoS ONE, 2018, 13, e0206796.	2.5	30
32	HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 566-573.	2.1	14
33	Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. AIDS Research and Therapy, 2017, 14, 1.	1.7	37
34	Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the XpertÂ® MTB/RIF era: a cohort study. BMC Infectious Diseases, 2017, 17, 433.	2.9	10
35	Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. BMJ Open, 2017, 7, e014679.	1.9	9
36	Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis. BMC Pulmonary Medicine, 2017, 17, 149.	2.0	28